SDHA Secondary Findings in Germline Testing: Counseling and Surveillance Considerations

Authors

Catherine M Skefos
Pamela L Brock
Erica Blouch
Samantha E Greenberg

Publication Date

1-1-2024

Journal

Endocrine Oncology

Abstract

This commentary explores the complexities faced by clinicians when encountering a secondary SDHA pathogenic variant (PV) in patients without a personal or family history of SDHA-related tumors. The increasing use of germline multi-gene panel testing has led to a rise in such secondary findings, necessitating a nuanced approach to counseling, surveillance, and decision-making. We aim to discuss the current data surrounding the penetrance of SDHA PVs, the spectrum of screening guidelines, recommendations for educating individuals and families about their secondary findings, and the need for future research to optimize care for these individuals. Practical recommendations for clinicians dealing with patients with secondary SDHA findings include acknowledging the limitations of existing guidelines, fostering shared decision-making, and considering specialist referrals. Overall, the evolving landscape of SDHA penetrance data warrants ongoing reassessment of surveillance approaches.

Keywords

genetic counseling, hereditary paraganglioma, incidental findings, paraganglioma, SDHx, secondary findings

Comments

PMID: 38770192